| [1] |
王乙钦, 李顺, 曾小芳, 等. 环状RNA circEIF6在肝细胞癌中的表达及功能研究[J/CD]. 中华普通外科学文献（电子版）, 2021, 15(4): 252-257.
|
| [2] |
Finn RS, Zhu AX, Farah W, et al. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis[J]. Hepatology, 2018, 67(1): 422-435.
|
| [3] |
Ghosh S. Cisplatin: the first metal based anticancer drug[J]. Bioorg Chem, 2019, 88: 102925.
|
| [4] |
Li P, Song R, Yin F, et al. circMRPS35 promotes malignant progression and cisplatin resistance in hepatocellular carcinoma[J]. Mol Ther, 2022, 30(1): 431-447.
|
| [5] |
Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses[J]. Nat Rev Cancer, 2018, 18(3): 139-147.
|
| [6] |
Twomey JD, Zhang B. Cancer Immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics[J]. AAPS J, 2021, 23(2): 39.
|
| [7] |
Glorieux C, Xia X, You X, et al. Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer[J]. J Adv Res, 2022, 40: 109-124.
|
| [8] |
Zhu H, Liu D, Deng S. Cisplatin promotes PD-L1 expression in A549 human lung adenocarcinoma cells via activating the ERK pathway[J]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2021, 37(10): 891-896.
|
| [9] |
Shen B, Huang D, Ramsey AJ, et al. PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma[J]. Br J Cancer, 2020, 122(5): 640-647.
|
| [10] |
Sheng Q, Zhang Y, Wang Z, et al. Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells[J]. Clin Exp Immunol, 2020, 200(1): 45-52.
|
| [11] |
Hao X, Sun G, Zhang Y, et al. Targeting immune cells in the tumor microenvironment of HCC: new opportunities and challenges[J]. Front Cell Dev Biol, 2021, 9: 775462.
|
| [12] |
Xu L, Zhang K, Ma X, et al. Boosting cisplatin chemotherapy by nanomotor-enhanced tumor penetration and DNA adducts formation[J]. J Nanobiotechnology, 2022, 20(1): 429.
|
| [13] |
Muraro E, Vinante L, Fratta E, et al. Metronomic chemotherapy: anti-tumor pathways and combination with immune checkpoint inhibitors[J]. Cancers (Basel), 2023, 15(9): 2471.
|
| [14] |
Zhang P, Liu J, Li W, et al. Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1[J]. Cancer Med, 2018, 7(7): 3178-3187.
|
| [15] |
Wangpaichitr M, Kandemir H, Li YY, et al. Relationship of metabolic alterations and PD-L1 expression in cisplatin resistant lung cancer[J]. Cell Dev Biol, 2017, 6(2): 183.
|
| [16] |
Li Y, Zhai Y, Chen Y. GATA1-induced upregulation of LINC01503 promotes carboplatin resistance in ovarian carcinoma by upregulating PD-L1 via sponging miR-766-5p[J]. J Ovarian Res, 2021, 14(1): 108.
|
| [17] |
Wu M, Huang Q, Xie Y, et al. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation[J]. J Hematol Oncol, 2022, 15(1): 24.
|
| [18] |
周红建, 李军, 夏建国. 顺铂诱导脑胶质瘤U87细胞的PD-L1表达及耐药机制的研究[J]. 中国现代应用药学, 2022, 39(9): 1155-1161.
|
| [19] |
Amornsupak K, Thongchot S, Thinyakul C, et al. HMGB1 mediates invasion and PD-L1 expression through RAGE-PI3K/AKT signaling pathway in MDA-MB-231 breast cancer cells[J]. BMC Cancer, 2022, 22(1): 578.
|
| [20] |
Gao Y, Sun Z, Gu J, et al. Cancer-associated fibroblasts promote the upregulation of PD-L1 expression through Akt phosphorylation in colorectal cancer[J]. Front Oncol, 2021, 11: 748465.
|
| [21] |
Zhang H, Yuan X, Yang Y, et al. Cathelicidin LL-37 promotes EMT, migration and metastasis of hepatocellular carcinoma cells in vitro and mouse model[J]. Cell Adh Migr, 2023, 17(1): 20-34.
|
| [22] |
Du L, Wang L, Yang H, et al. Sex comb on midleg like-2 accelerates hepatocellular carcinoma cell proliferation and metastasis by activating Wnt/β-catenin/EMT signaling[J]. Yonsei Med J, 2021, 62(12): 1073-1082.
|
| [23] |
熊玮, 刘慧敏, 刘平, 等. lncRNA LSINCT5通过miR-451调控肺癌细胞侵袭、迁移及顺铂敏感性的实验研究[J]. 中国免疫学杂志, 2022, 38(11): 1349-1354.
|